Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
uniQure NVLTS:0EE0 +2.18%43 Buyback Yield % is -11.26 as of Jul. 20, 2026. GuruFocus rates LTS:0EE0 with a GF Score™ of 43/100 and a GF Value™ of $5.84 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 740 Biotechnology companies, uniQure NV ranks worse than 53.51% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for uniQure NV's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0EE0 vs ALMS, ARQT, DYN: Buyback Yield % Comparison
For the Biotechnology subindustry, uniQure NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where uniQure NV's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (LTS:0EE0) has a Buyback Yield % of -11.26 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #396 out of 740 companies in the Biotechnology industry, placing it in the top 53.5%.
Is uniQure NV's Buyback Yield % too high?
uniQure NV's current Buyback Yield % is -11.26. Based on the distribution chart, uniQure NV ranks #396 out of 740 companies in the Biotechnology industry, which is below the industry midpoint. Overall, uniQure NV has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Buyback Yield % compare to ALMS and ARQT?
According to the Biotechnology industry distribution chart, uniQure NV ranks #396 out of 740 companies for Buyback Yield %. This places uniQure NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on uniQure NV and its competitors. uniQure NV's current Buyback Yield % is -11.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.84, compared to a current price of $40.30 — trading 590.1% above its estimated fair value. The current Buyback Yield % is -11.26. uniQure NV's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current Buyback Yield % is -11.26 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (LTS:0EE0) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $40.30 is trading 590.1% above its estimated GF Value™ of $5.84.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for LTS:0EE0:
Buyback Yield %: -11.26
GF Value™: $5.84 vs. price of $40.30 (590.1% above fair value)
No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
43GF Score
Get the complete analysis for LTS:0EE0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0EE0 has been successfully added to your 
